Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories.
Antineoplastic Agents
Asians
Breast Neoplasms
Healthcare Disparity
Thailand
Journal
Journal of breast cancer
ISSN: 1738-6756
Titre abrégé: J Breast Cancer
Pays: Korea (South)
ID NLM: 101314183
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
25
02
2022
revised:
09
04
2022
accepted:
01
05
2022
pubmed:
4
6
2022
medline:
4
6
2022
entrez:
3
6
2022
Statut:
ppublish
Résumé
Breast cancer (BC) treatment has shifted from chemotherapy to targeted therapy. Several targeted agents have demonstrated an improvement in survival. Given that national healthcare resources were correlated with the cancer mortality-to-incidence ratio, we compared access to BC drugs in Thailand with that in other Asian countries. BC experts involved in the Breast International Group (BIG)-Asia in six representative groups for countries or special administrative region (SAR) in Asia (Hong Kong SAR, Japan, Korea, Taiwan, Thailand, and Singapore) were invited to participate in the survey. The questionnaire addressed national health reimbursement schemes, molecular testing for early BC (EBC), availability and accessibility of BC drugs. Accessibility and reimbursement of the drugs were reported based on their listing as essential medicines in the World Health Organization Model List of Essential Medicines (WHO-EML) and their nomination as effective drugs in the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). The study was approved by all participating BIG-Asia organizations in November 2021. Genomic tests for EBC were non-reimbursable in all surveyed territories. Reimbursement and co-payment of BC drugs vary between and within these regions (particularly Thailand). Most drugs in the WHO-EML and ESMO-MCBS (A/B for EBC and 4/5 for advanced BC) were accessible in all surveyed territories. However, the accessibility of effective but costly WHO-EML and ESMO-MCBS drugs was not uniform in Thailand. There was an evident disparity for individuals covered by the Thai Social Security/Universal Health Coverage schemes. Essential BC drugs are generally accessible in selected BIG-Asia countries or SAR. There is a disparity in accessing high-cost drugs in Thailand compared with other Asian territories.
Identifiants
pubmed: 35657002
pii: 25.e21
doi: 10.4048/jbc.2022.25.e21
pmc: PMC9250880
doi:
Types de publication
Journal Article
Langues
eng
Pagination
207-217Informations de copyright
© 2022 Korean Breast Cancer Society.
Déclaration de conflit d'intérêts
SI received an honorarium from Novartis.
Références
PLoS One. 2017 Sep 8;12(9):e0184372
pubmed: 28886126
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
CA Cancer J Clin. 2020 Mar;70(2):105-124
pubmed: 32068901
Arch Pathol Lab Med. 2018 Jun;142(6):735-741
pubmed: 29528718
WHO South East Asia J Public Health. 2018 Sep;7(2):62-66
pubmed: 30136662
Jpn J Clin Oncol. 2019 Dec 18;49(11):1029-1036
pubmed: 31287883
Ann Oncol. 2015 Aug;26(8):1547-73
pubmed: 26026162
Health Policy Plan. 2020 Nov 20;35(9):1159-1167
pubmed: 33212481
Curr Oncol. 2019 Apr;26(2):89-93
pubmed: 31043808
Ann Oncol. 2017 Nov 01;28(11):2633-2647
pubmed: 28950323
Cancer. 2010 Jul 1;116(13):3112-8
pubmed: 20564629
ESMO Open. 2019 Jul 17;4(4):e000483
pubmed: 31423334
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Epidemiol Glob Health. 2014 Jun;4(2):115-24
pubmed: 24857179